Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matti Annala

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
Molecular Cancer Therapeutics|November 13, 2025
NOUS-209 off-the-shelf immunotherapy has the potential to hit primary and metachronous colorectal and urothelial cancer in Lynch syndromeLorenzo De Marco, Elisa Micarelli, Joni Panula, et al.
European Urology|March 6, 2017
Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate CancerMatti Annala, Werner J Struss, Evan W Warner, et al.
Oncotarget|March 10, 2015
Recurrent SKIL-activating rearrangements in ETS-negative prostate cancerMatti Annala, Kati Kivinummi, Joonas Tuominen, et al.
JCO Precision Oncology|May 4, 2022
Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate CancerNicolette M Fonseca, Kim Van der Eecken, Cameron Herberts, et al.
JAMA Oncology|May 6, 2016
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate CancerAlexander W Wyatt, Arun A Azad, Stanislav V Volik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2017
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation TherapyHimisha Beltran, Alexander W Wyatt, Edmund C Chedgy, et al.
The Journal of Pathology|July 18, 2018
Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinomaEdmund Cp Chedgy, Gillian Vandekerkhove, Cameron Herberts, et al.
Journal of the National Cancer Institute|September 7, 2023
Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trialTakayuki Sumiyoshi, Xiaofei Wang, Evan W Warner, et al.
European Urology|January 23, 2019
Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial CarcinomaNora Sundahl, Gillian Vandekerkhove, Karel Decaestecker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2021
<i>BRCA2</i>, <i>ATM</i>, and <i>CDK12</i> Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical AggressionEvan Warner, Cameron Herberts, Simon Fu, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Molecular Cancer Therapeutics|November 13, 2025
NOUS-209 off-the-shelf immunotherapy has the potential to hit primary and metachronous colorectal and urothelial cancer in Lynch syndromeLorenzo De Marco, Elisa Micarelli, Joni Panula, et al.
European Urology|March 6, 2017
Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate CancerMatti Annala, Werner J Struss, Evan W Warner, et al.
Oncotarget|March 10, 2015
Recurrent SKIL-activating rearrangements in ETS-negative prostate cancerMatti Annala, Kati Kivinummi, Joonas Tuominen, et al.
JCO Precision Oncology|May 4, 2022
Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate CancerNicolette M Fonseca, Kim Van der Eecken, Cameron Herberts, et al.
JAMA Oncology|May 6, 2016
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate CancerAlexander W Wyatt, Arun A Azad, Stanislav V Volik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2017
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation TherapyHimisha Beltran, Alexander W Wyatt, Edmund C Chedgy, et al.
The Journal of Pathology|July 18, 2018
Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinomaEdmund Cp Chedgy, Gillian Vandekerkhove, Cameron Herberts, et al.
Journal of the National Cancer Institute|September 7, 2023
Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trialTakayuki Sumiyoshi, Xiaofei Wang, Evan W Warner, et al.
European Urology|January 23, 2019
Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial CarcinomaNora Sundahl, Gillian Vandekerkhove, Karel Decaestecker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2021
<i>BRCA2</i>, <i>ATM</i>, and <i>CDK12</i> Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical AggressionEvan Warner, Cameron Herberts, Simon Fu, et al.
Pageof 7